r Heart rate is increased in chronic hypoxia and we tested whether this is the result of increased sympathetic nervous activity, reduced parasympathetic nervous activity, or a non-autonomic mechanism.
Introduction
Acute exposure to hypoxia accelerates resting heart rate (HR) by facilitating sympathoactivation and parasympathetic withdrawal (Koller et al. 1988; . As hypoxic exposure extends, HR remains elevated despite the progressive restoration of arterial O 2 content (C aO 2 ) that occurs with acclimatization Hansen & Sander, 2003; Naeije, 2010) . The persistent activation of the sympathetic nervous system that accompanies chronic hypoxia (Hansen & Sander, 2003) may seem an obvious explanation for the elevated HR. Nevertheless, pharmacological inhibition of β-adrenergic receptors did not abolish the increase in HR associated with 2 weeks of exposure to high altitude (HA) (Hughson et al. 1994; Wolfel et al. 1994) , implying a contribution of sustained parasympathetic withdrawal. Surprisingly, however, administration of muscarinic receptor antagonists induced a more pronounced increase in HR after 9 weeks at HA than at sea level (SL), indicating increased parasympathetic activity (Boushel et al. 2001) . These conflicting observations could relate to methodological differences, most notably the inhibition of different receptor types, as well as different subject groups and HA exposure protocols. The interpretation is further complicated since all these studies inhibited only one receptor type, requiring divergent analytical approaches to assess the respective contributions of the sympathetic and parasympathetic nervous system to the increased HR. Another explanation could be that an unknown, non-autonomic mechanism contributes to the increased HR in chronic hypoxia. Such changes of intrinsic heart rate could be demonstrated during simultaneous inhibition of β-adrenergic and muscarinic receptors, which has to our knowledge never been conducted in chronic hypoxia.
The aim of this study was to advance our understanding of the regulation of the increased HR in chronic hypoxia by isolating the relative contributions of the sympathetic and parasympathetic nervous systems as well as of potential non-autonomic mechanisms. In seven lowlanders exposed for 15-18 days to HA, we compared HR between SL and HA after pharmacological inhibition of either muscarinic or β-adrenergic receptors, or both receptor types in combination. Based on findings in acute hypoxia , we hypothesized that both sympathoactivation and parasympathetic withdrawal contribute to the increased HR in chronic hypoxia, so that individual inhibition of either receptor type would not prevent the acceleration of HR at HA. We further hypothesized that full cardiac autonomic blockade would abolish the HA-induced increase in HR and hence exclude a contribution of a non-autonomic mechanism.
Methods

Ethical approval
This study was approved by the ethical committee of the Swiss Federal Institute of Technology (EK 2011-N-51) and conducted in accordance with the current version of the Declaration of Helsinki. All subjects gave written and oral consent to participation.
Participants
Seven healthy, male, Caucasian lowlanders (26 ± 4 years; 180 ± 1 cm; 76 ± 6 kg) were recruited as study subjects. All were physically active on a recreational basis. Subjects refrained from travelling to altitudes > 2000 m within the last 4 weeks before the experiments.
Protocol
This study took place at the University of Zürich, Switzerland (460 m, referred to as SL) and during a 4-week sojourn at the Jungfraujoch research station in the Swiss Alps (3454 m, referred to as HA). This station offers private bedrooms for all subjects, kitchen facilities and living space, all with normal room temperatures. Subjects were transported to HA and back to SL by train. During the HA sojourn, they preserved physical activity by hiking, mountaineering and ergometer cycling. Drinking water was always available ad libitum and subjects were instructed to maintain their habitual diets, for which they ordered the required groceries. As previously reported, both body weight and composition were maintained throughout the HA sojourn (Jacobs et al. 2012) .
Experiments were scheduled during the last week before ascent and then after 15-18 days at HA. At both altitudes, the experiments followed the same protocol and were conducted at normal room temperature, by the same investigators, and using the same equipment. Participants reported to the laboratory on two days, separated by 2-4 days. On both days, a venous catheter was inserted into an antecubital vein. An additional catheter was inserted under local anaesthesia into a radial artery on the second day only. After catheterization, subjects were placed in a semi-recumbent position. On the second day, 2 ml of arterial blood was collected and analysed in a haemoximeter (ABL 800, Radiometer, Copenhagen, Denmark). Subjects then remained still for ß10 min, while arterial pressure was continuously monitored on the finger by the volume clamp method (Finometer PRO, Finapres Medical Systems BV, Amsterdam, The Netherlands). HR was derived as the inverse of the inter-beat interval. Cardiac stroke volume was determined from the blood pressure waveform by a three-element model of arterial input impedance (Modelflow) incorporating age, sex, height and weight (Wesseling et al. 1993) . Cardiac output was calculated as HR × stroke volume. Data were recorded at a frequency of 1 kHz (Powerlab, ADInstruments, Bella Vista, Australia). For the analysis we used the 120 successive heart beats with the lowest variation.
On the first day, measurements were conducted without receptor inhibition (control, CONT), and then after administration of glycopyrrolate (GLYC). On the second day, measurements were performed after administration of propranolol (PROP), and then after additional administration of GLYC (PROP+GLYC). Neither the investigators nor the subjects were blinded towards the drug condition.
Drug administration
GLYC was infused for 5 min at a rate of 2.5 μg kg −1 min −1 . Subsequently, an additional bolus of 50 μg was injected every 2 min until the HR response to the bolus was < 10%. Receptor inhibition was thereafter maintained by continuous infusion of 0.05 μg kg −1 min −1 until termination of the measurements. PROP was infused at a rate of 15 μg kg −1 min −1 for 15 min. β-Receptor inhibition was subsequently challenged by infusion of a 60 μg bolus of isoprenaline and an additional 1 mg bolus of PROP was injected every 2 min until the HR response to isoprenaline was < 10 %. A continuous administration of 0.8 μg kg −1 min −1 was thereafter maintained throughout the measurements. After completion of the PROP experiments, GLYC was administered according to the protocol specified above, while sustaining the continuous infusion of PROP.
All drugs were administered by means of an automated infusion pump (Harvard Apparatus, Cambridge, UK). During GLYC administration, the final dose was 4.3 ± 0.5 mg at SL and 3.9 ± 0.3 mg at HA. During PROP administration, the final dose was 21.7 ± 1.6 mg at SL and 21.0 ± 1.9 mg at HA. During the PROP+GLYC administration, the final doses of the two drugs were 26.7 ± 1.8 (including the dose applied in the preceding PROP experiment) and 4.6 ± 0.3 mg at SL and 25.6 ± 2.6 and 3.7 ± 0.7 mg at HA.
Venous noradrenaline
At SL as well as after 2, 10 and 26 days at HA, 5 ml of venous blood was collected. Blood compartments were separated by centrifugation and the plasma immediately frozen in liquid nitrogen and stored at -80°C. Venous noradrenaline was measured in these samples as a marker for sympathetic activity by liquid chromatography-mass spectrometry.
Blood withdrawal for other experiments
Over the course of the 5 weeks preceding ascent to HA, a total of ß150 ml of whole blood was withdrawn for different study purposes. At HA, a total of ß120 ml of blood was withdrawn at various time points before the experiments reported here were conducted.
Statistics
To assess the effect of HA within the different drug conditions, we used a mixed model for repeated measures approach, unless otherwise noted. Level of the subject was entered as a random effect while drug and altitude levels were entered as fixed effects. For changes in venous noradrenaline concentration, time from start of HA sojourn was entered as a fixed effect. Where applicable, Tukey's post hoc test was used for pairwise comparison. HA-induced changes in indices of arterial oxygenation were assessed by Student's t test, and SAS Enterprise Guide 6 (SAS Institute Inc., Cary, NC, USA) was used for the analysis. A P-value < 0.05 was considered significant and values represent means ± SD. (Table 1) Arterial O 2 tension and oxyhaemoglobin saturation were reduced at HA (P < 0.001). This was, however, compensated by an increase in haematocrit (P = 0.008) and haemoglobin concentration (P = 0.002), so that C aO 2 was higher at HA than at SL (P = 0.04).
Results
Arterial blood analysis
Heart rate (Fig. 1) During the CONT treatment, HR was 9.7 ± 7.9 beats min −1 higher at HA than at SL (P = 0.007). This effect of HA was affected by the autonomic antagonists (P = 0.006). Specifically, while HR was increased at HA by 7.6 ± 4.0 beats min during the PROP treatment (P < 0.001), it was only insignificantly higher than at SL during the GLYC treatment (2.3 ± 6.0 beats min −1 , P = 0.28) and PROP+GLYC treatment (2.3 ± 5.4 beats min −1 , P = 0.25).
Haemodynamics (Fig. 2)
The effect of HA on cardiac stroke volume also depended on the type of receptor inhibition (P = 0.04). While cardiac stroke volume was only insignificantly lower at HA than at SL during the CONT treatment (-0.2 ± 19.2 ml, P = 0.8), a reduction was observed at HA during the PROP (-23.0 ± 13.4 ml, P < 0.001), GLYC (-12.8 ± 11.9 ml, P = 0.01) and PROP+GLYC treatments (-25.7 ± 16.1 ml, P < 0.001). Similarly, the effect of HA on cardiac output tended to depend on the drug condition (P = 0.06). While HA numerically increased cardiac output during the CONT treatment by 1.1 ± 2.2 l min −1 (P = 0.2), it reduced cardiac output during the PROP treatment by 0.8 ± 0.8 l min −1 (P = 0.02), during the GLYC treatment by 1.1 ± 1.1 l min −1 (P = 0.02) and during the PROP+GLYC treatment by 2.0 ± 1.5 l min −1 (P = 0.002).
Mean arterial pressure was increased at HA (P = 0.001) and this response was not affected by the autonomic antagonists (P = 0.9). The respective increases during the CONT, PROP, GLYC and PROP+GLYC treatment 
Venous noradrenaline
Venous noradrenaline concentration was 0.9 ± 0.4 nmol l −1 at SL and similar (1.1 ± 0.5 nmol l −1 , P = 0.7) on the second day at HA. Subsequently, noradrenaline concentration increased to 2.7 ± 1.5 nmol l −1 (P = 0.03) on day 10 and to 3.0 ± 1.2 nmol l −1 (P = 0.007) on day 26 at HA.
Discussion
As expected, HR during the CONT treatment was higher at HA than at SL despite complete restoration of C aO 2 . A similar HA-induced increase in HR was observed when β-adrenergic, but not when muscarinic, receptors were inhibited. These results suggest that cardiac parasympathetic withdrawal persists throughout HA acclimatization and constitutes the dominating cardioacceleratory mechanism. The absence of a HA-induced increase in HR during combined inhibition of β-adrenergic and muscarinic receptors rules out a relevant contribution of a non-autonomic mechanism. Acceleration of resting HR occurs within the first seconds of hypoxic exposure. This acute response is governed by a combination of sympathoactivation and parasympathetic withdrawal, although the respective contributions are unclear . As hypoxic exposure extends, sympathoactivation persists or increases further (Hansen & Sander, 2003) , as illustrated in the present study by circulating noradrenaline. Surprisingly, the similar HR between SL and HA during the GLYC treatment reveals that the contribution of this sustained sympathoactivation to the accelerated HR in chronic hypoxia is minor. A potential explanation could be that the chronically elevated sympathetic activity facilitates a down-regulation of cardiac β-adrenergic receptor function and/or density. This is supported by the blunted tachycardic response of humans to isoproterenol infusion after acclimatization to HA (Richalet et al. 1988) .
The effect of chronic hypoxia on parasympathetic activity is poorly understood, since direct measurement techniques are not available in humans. Circulating acetylcholine concentration may seem an obvious marker for parasympathetic activity, but experimental evidence does not support this (Fujii et al. 1997) . Instead, spectral analysis of HR variability has been used and suggested that parasympathetic withdrawal persists even after 18 months at HA (Dhar et al. 2014) . However, this finding should be interpreted with caution, since parasympathetic indices of HR variability may be influenced at HA by the concomitantly increased sympathetic activity and/or pulmonary ventilation (Chapleau & Sabharwal, 2011) . Nevertheless, the inability of PROP to prevent the HA-induced increase in HR in the present and earlier studies (Hughson et al. 1994; Wolfel et al. 1994 ) supports persistent parasympathetic withdrawal in chronic hypoxia. In acute hypoxia, parasympathetic withdrawal is likely to occur as a reflex response to the activation of pulmonary stretch receptors by enhanced ventilation (Kato et al. 1988) . Ventilatory acclimatization facilitates further increases in pulmonary ventilation in chronic hypoxia (Bender et al. 1989) , which may explain persisting parasympathetic withdrawal. While the present results support attenuated parasympathetic activity in chronic hypoxia, Boushel et al. (2001) observed that muscarinic inhibition induced a larger increase in HR after 9 weeks at 5300 m than at SL, and accordingly concluded that parasympathetic tone is increased in chronic hypoxia. Since parasympathetic modulation of HR was assessed without β-adrenergic inhibition, this J Physiol 595.5 conclusion is based on the assumption that the effect of a given parasympathetic tone on HR was not affected by the severe sympathoactivation that was observed at HA in these subjects (Hansen & Sander, 2003) . Another obvious difference to the present study is the longer exposure to more severe HA. The restored C aO 2 in our subjects indicates that the most functionally important acclimatization processes were completed when the experiments at HA were conducted. Accordingly, it appears unlikely that parasympathetic withdrawal would have reversed to parasympathetic activation at a later point of exposure. Nevertheless, the longer and more severe hypoxia in the study of Boushel et al. (2001) may have increased the density of cardiac muscarinic receptors and hence the bradycardic effect evoked by a given parasympathetic outflow (Kacimi et al. 1993) . Another explanation could be that the large increase in arterial pressure that was observed in that study (Calbet, 2003) enhanced parasympathetic tone by activation of arterial baroreceptors. In the present study, the HA-induced increase in arterial pressure was milder, presumably due to the lower altitude.
In another study, a larger HR response to GLYC administration than at SL was observed after the same duration of HA exposure as in the present study (Bao et al. 2002) . Unexpectedly, HR in the absence of receptor inhibition was not higher at HA than at SL in that study, which may explain the more pronounced difference from HR measured at HA after muscarinic inhibition. Notably, this study also applied PROP, which did not prevent the tachycardic effect of HA. This is in agreement with the present results and provides evidence that cardiac parasympathetic activity was not elevated at HA.
In order to examine whether chronic hypoxia increases HR by a non-autonomic mechanism, we performed simultaneous inhibition of β-adrenergic and muscarinic receptors. Such full autonomic inhibition has previously ruled out a contribution of a non-autonomic mechanism to the increased resting HR in acute hypoxia . Nevertheless, functional and structural cardiac remodelling occurs in lowlanders after only 10 days at HA (Stembridge et al. 2014) and it was unclear whether this encompasses an increase in the intrinsic depolarization rate of cardiac pacemaker cells. Furthermore, chronic hypoxia-induced changes in arterial pH and/or electrolyte concentration (Severi et al. 2002) or simply an unknown mechanism could have increased intrinsic HR independent of structural changes. The observation that HR was similar at SL and HA during the PROP+GLYC treatment, however, suggests that a non-autonomic mechanism does not increase HR in chronic hypoxia.
We unexpectedly observed that cardiac stroke volume was not reduced at HA during the CONT treatment. A decrease in stroke volume usually occurs within the first week and thereafter persists throughout HA exposure, likely due to a reduction in plasma volume (Siebenmann et al. 2013) . Since stroke volume decreased at HA in all other drug conditions and also without drugs at a later point of the HA sojourn (Siebenmann et al. 2013) , the absence of a decrease during the CONT treatment presumably reflects a type 2 error. Interestingly, the reduction in stroke volume at HA during the GLYC and PROP+GLYC treatments, where HR did not increase, confirms that a reduced diastolic filling time is not a major component of the HA-induced reduction in stroke volume (Siebenmann & Lundby, 2015) .
There are several methodological aspects to consider. First, it needs to be appraised whether autonomic regulation of HR after 2 weeks of HA exposure is representative for chronic hypoxia. In support, circulating noradrenaline in the present and a previous study indicates that sympathoactivation reaches a plateau within the first 2 weeks at HA. Furthermore, the limited insight derived from spectral analysis of HR variability supports that the observed withdrawal of parasympathetic activity is at least qualitatively representative for chronic hypoxia (Dhar et al. 2014) . Whether potential changes in autonomic receptor function and/or density affect autonomic regulation of HR at a later point of hypoxic exposure, however, remains to be determined. Second, it needs to be considered whether experimental blood withdrawal affected our study outcome. As reported previously (Siebenmann et al. 2013) , red cell volume at the time point of the HA experiments was similar to SL, suggesting that the blood withdrawal prevented the ß2.5% expansion in red cell volume that would have been expected at that point (Siebenmann et al. 2015a) . Nevertheless, the contribution of red cell volume expansion to the restoration of C aO 2 at this altitude is small compared to those of plasma volume reductions and increases in arterial O 2 saturation (Siebenmann et al. 2015a) . This is illustrated in the present study by the observation that, despite the blood withdrawal, C aO 2 was higher at HA than at SL. It therefore seems unlikely that the experimental blood withdrawal exerted a confounding effect. A third methodological aspect to consider concerns the use of PROP and GLYC. PROP is not only a β-adrenergic antagonist but also possesses membrane-stabilizing capabilities, which may contribute to its bradycardic effect (Boucher et al. 1992) . Nevertheless, since the applied doses of PROP were similar at SL and HA, this membrane stabilizing effect was presumably also similar and is hence unlikely to have contributed to the increased HR at HA during PROP. GLYC, on the other hand, is a non-selective muscarinic antagonist. Isolation of sympathetic control of HR requires that all effects of parasympathetic modulation are prevented. Since different muscarinic receptor types occur in the human heart (Olshansky et al. 2008) , a non-specific muscarinic antagonist seems appropriate for this purpose. More specific studies could now be conducted to evaluate the roles of the different muscarinic receptor types in the HR response to HA. It further needs to be considered whether PROP and GLYC completely inhibited β-adrenergic and muscarinic receptors, respectively. Adequate dosing of PROP was confirmed by isoproterenol challenge, and the final doses conformed to those that evoked complete cardiac β-adrenergic inhibition in dogs (Jose & Taylor, 1969) . Although muscarinic inhibition could not be challenged by an agonist, GLYC was applied until additional administration did not evoke a further tachycardic response and the final doses highly exceeded those used in related studies (Boushel et al. 2001; Bao et al. 2002) . Finally, the absence of an effect of HA on HR during the PROP+GLYC treatment supports that inhibition of the two receptor types was adequate. Nevertheless, during both the GLYC and the PROP+GLYC treatments two subjects still presented with a notable increase in HR at HA (Fig. 1 ) and in one case, this was the same subject. The reason for this persisting increase is unclear since these subjects had received similar doses of GLYC as the other subjects. Furthermore, circulating noradrenaline concentration does not suggest a more pronounced HA-induced sympathoactivation. It could be speculated that cardiac β-adrenergic receptor down-regulation in chronic hypoxia (Richalet et al. 1988 ) is subject to intra-individual variability so that a tachycardic effect of the increased sympathetic activity at HA was preserved in some subjects.
A limitation of this study is the small number of subjects included; we cannot rule out that the slight numerical increases in HR at HA during the GLYC and PROP+GLYC treatments would have reached statistical significance in a larger subject cohort. Nevertheless, since the slight HR increases at HA during the GLYC and PROP+GLYC treatments were considerably smaller than those observed during the CONT and PROP treatments, they do not contradict a dominating role of parasympathetic withdrawal. A further limitation is that our study was not double-blinded. Subject blinding was, however, not possible due to the obvious side effects of GLYC (dry mouth, difficulty in urinating). Nevertheless, HR in a similar study proved insensitive to a placebo effect . Furthermore, the 120 heart beats included in the analysis were selected by our statistics software and not by a researcher. Accordingly, we are confident that blinding of either subjects or researchers would not have changed the study outcome.
In conclusion, our results suggest that parasympathetic withdrawal persists and represents the main mechanism by which resting HR is increased in chronic hypoxia, whereas the sustained sympathoactivation does not play a major role. Furthermore, our results do not support a contribution of a non-autonomic mechanism.
Future studies could investigate whether changes in cardiac muscarinic receptor density or function affect the parasympathetic regulation of HR during longer hypoxic exposure.
